New drug targets gene flaw in Tough-to-Treat cancers
NCT ID NCT07080619
Summary
This study is testing an investigational drug called SC-101 for people with advanced breast cancer and other solid tumors that have a specific genetic feature called NECTIN4 amplification. About 120 participants whose cancer has progressed after standard treatments will receive weekly infusions of SC-101. The main goal is to see if the drug shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.